Board of Directors
The Board of Directors plays a crucial role in the governance of CCTF. They are responsible for setting the organization’s strategic direction, ensuring financial stability, and upholding its mission. The board also oversees policies and procedures, while providing support and accountability for the executive leadership. Their commitment and expertise are essential for fostering transparency and building trust with the community they serve.
.png)
Dr. Aleksi is a physician-scientist specializing in cardiology, oncology, and molecular imaging. Board-certified in Internal Medicine and Medical Oncology (FRCPC, Canada), she has completed advanced fellowships in Thoracic and Neuroendocrine Tumors as well as Theranostics and Cardio-Oncology, integrating cancer care with molecular imaging and radiopharmaceutical therapy.
Dr. Aleksi is currently a Medical Oncologist at the Arthur Child Comprehensive Cancer Centre and holds a faculty appointment as a Clinical Assistant Professor at the Cumming School of Medicine, University of Calgary. Her clinical focus is on neuroendocrine tumors (NETs) and endocrine tumors (ETs), with a particular emphasis on the integration of theranostic strategies—such as peptide receptor radionuclide therapy (PRRT) and radioligand-based diagnostics—into personalized cancer care. She leads one of Alberta’s largest clinical programs dedicated to NET and ET patients.
In parallel with her clinical work, Dr. Aleksi has played a leading role in establishing several provincial initiatives to enhance NET care infrastructure, patient advocacy, and public awareness. These include founding Alberta’s first NET patient advocacy committee, creating the province’s first comprehensive NET registry, and launching targeted awareness campaigns and philanthropic programs. Dr. Aleksi has several leadership appointments, contributing to Canadian clinical guideline development, national advisory boards, CDA, radionuclide working groups, etc.
Dr. Aleksi has authored multiple peer-reviewed publications across cardiovascular and oncologic disciplines and is a recipient of several competitive research grants. She remains actively engaged in both clinical trials and translational studies.
With a career bridging cardiovascular medicine, oncology, and nuclear imaging, Dr. Aleksi continues to advance the field of precision oncology—positioning herself at the forefront of cancer theranostics research and implementation in Canada and internationally.
Art Agolli is a successful serial entrepreneur. He has been involved with several successful energy companies
as a founder and executive. Apart from energy Mr. Agolli a champion of innovation, disruptive technologies
and improvement of Canadian healthcare and higher education.
Mr. Agolli founded Equity Health Services, a healthcare diagnostic and solution provider company during the
Covid pandemic. The company played an important role during the Covid pandemic in Canada and
internationally. Currently, Mr. Agolli is the chairman of Dsrupt Energy and lead director of Westgate Energy.
Prior, Mr. Agolli was a business development executive with Koch Industries Inc, the largest privately held
company in North America.
He started his career at the World Bank in Washington DC. Mr. Agolli received a Bachelor’s in International Relations and Master`s Degree in Management from Grand Valley State University in Michigan, USA.
Mr. Agolli is quite active in the community supporting various philanthropic causes. He is also the founder and Director of Canadian Albanian Development Foundation and also serves in the
Advisory Board of Schulic School of Engineering (University of Calgary).
Dr. Irving Berkowitz is the Emeritus Dean of Academic Affairs at Palm Beach State College, where he served for 8 years before retiring in 2020. He previously held leadership roles including Executive VP at Bermuda College and has over 40 years of experience in higher education as a professor, dean, and academic VP. He is a noted scholar and public speaker on the Holocaust, antisemitism, social policy, and organization theory.
Early in his career, he was recognized as a Distinguished University Professor and later named a Distinguished Alumnus of Ohio University and Tulane University. A son of Holocaust survivors, Dr. Berkowitz is deeply committed to social justice, civil rights, and Holocaust education.
In 1990, he was appointed a political and public policy advisor to the governments of Romania and Albania following the fall of Communism, a role he continues today. He authored U.S. and UN-funded initiatives to support civil society in these countries and was honored by their governments in 2015 for 25 years of service.
Dr. Berkowitz has received numerous awards, including:
- Induction into the Cleveland Heights High School Distinguished Alumni Hall of Fame (2015)
- Holocaust Fellowship at Yad Vashem (2016)
- Holocaust Scholar for the Southern U.S. March of the Living (2017)
- Oxford University Fellowship on Global Antisemitism (2018)
- Dr. Martin Luther King, Jr. Distinguished Leadership Award (2019)
- Adviser on Broadway's Harmony musical (2023)
Dr. Berkowitz earned his bachelors degree in Sociology from Ohio University, Masters degree in Social Policy and Planning from the University of North Carolina at Chapel Hill; and Doctoral
degree in Social Policy and Organization Theory from Tulane University in New Orleans. He completed his first post-doctoral certificate program in Austrian Economics from the Foundation for Economic Education at Irvington-on-Hudson. He also has a post-doctoral
certificate in Higher Education Leadership from Harvard University.
We are deeply honored and truly humbled to have Prof. Dr. Richard P. Baum serve as Chair of the CCTF Board of Directors, where his vision and expertise will help us expand our mission and impact worldwide
Prof. Dr. Richard P. Baum, Nuclear Medicine Physician at Curanosticum Wiesbaden, Germany, serves as President of the ICPO Academy for Theranostics and Chairman of the Scientific Advisory Board of the ICPO Foundation. Widely regarded as a pioneer and international authority in Radiomolecular Precision Oncology, he has made transformative contributions to the treatment of neuroendocrine tumors and prostate cancer.
With nearly four decades of experience, Prof. Baum has combined scientific innovation with clinical excellence to advance cancer therapy. Under his leadership, more than 2,000 NET patients worldwide have received over 7,000 Peptide Receptor Radionuclide Therapy (PRRT) treatments. His work has earned numerous prestigious honors, including the Mallinckrodt Award (1990), the GLORINET Award from the German NET Patients Support Group (2014), and the Saul Hertz Award from the SNMMI (2019)—a lifetime achievement recognition in nuclear medicine therapy.
Prof. Baum holds guest and associate professorships at institutions across the globe, including Michigan State University in the United States and Peking University Cancer Hospital in China. He is particularly celebrated for his groundbreaking research in Bad Berka, where he established the world’s first “Theranostics Empire,” guided by his life principles Rerum cognoscere causas and Carpe diem.
His scholarly impact is equally remarkable, with over 50 scientific publications and more than 42,000 citations—half of which were accumulated since 2020. Prof. Baum’s expertise continues to shape the future of theranostics, bringing unparalleled insight to the mission of the CCTF Foundation.
​
​
​
​
​
​
​
​
​
